Middle East and Africa HIV Diagnosis & Treatment Market Overview:
Middle East and Africa HIV Diagnosis & Treatment Market is expected to reach USD 12.7 billion at a CAGR 2.9% during the forecast period 2023-2032.
HIV prevalence in Africa, specifically in Southern region is very high as compared to North African region. Approximately 1 out of 4 is suffering from HIV. Southern and Eastern region of Africa has one of the highest prevalence rate of HIV, about 19 million people have HIV. While HIV prevalence is low in North Africa but the number of cases of HIV are increasing rapidly. There is no cure for HIV but drugs manufacturing companies are investing huge money in R&D to develop drugs for HIV. Over 3000 patients were died in sub Saharan Africa due to HIV in 2015. Following 10 countries from Africa consists of 80% of total HIV burden which are South Africa, Kenya, Malawi, Ethiopia, Mozambique, United Republic of Tanzania, Nigeria, Uganda, Zimbabwe and Zambia.
Middle East and Africa HIV Diagnosis & Treatment Market is growing moderately.
Study objectives of Middle East and Africa HIV Diagnosis & Treatment Market:
- To provide detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Middle East and Africa HIV Diagnosis & Treatment Market
- To provide insights about factors affecting the market growth in this region
- To analyze the Middle East and Africa HIV Diagnosis & Treatment Market based on various factors - price analysis, supply chain analysis, Porters Five Forces analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to two main geographies and their countries
- To provide detailed analysis of the market with respect to the current market size and future prospective
- To provide detailed analysis of the market for segments by diagnosis, by treatment, and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Middle East and Africa HIV Diagnosis & Treatment Market.
Middle East and Africa HIV Diagnosis & Treatment Market by Diagnosis, 2016, (%Market Share):
Key Players for Middle East and Africa HIV Diagnosis & Treatment Market:
Some of the key players in this market are: Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (US), Cipla Inc. (India), F. Hoffmann-La Roche Ltd (Switzerland), Gilead (US), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc.(US), ViiV Healthcare group of companies (UK), Merck & Co., Inc. (US).
Middle East and Africa HIV Diagnosis & Treatment Market Segment Insights:
Middle East and Africa HIV Diagnosis & Treatment Market has been segmented on the basis of diagnosis which comprise ELISA Test, Saliva Tests, Viral Load Test, Western Blot, and Others. On the basis of treatment, market is segmented into Protease inhibitors (PIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), Entry or fusion inhibitors, Integrase inhibitors, and others.
Regional Analysis of Middle East and Africa HIV Diagnosis & Treatment Market:
Considering the scenario of the Middle East and African HIV Diagnosis & Treatment market, Africa is believed to be the largest market for HIV Diagnosis & Treatment. Moreover, the Rest of Middle East and Africa is growing and it is the second largest market for Middle East and Africa HIV Diagnosis & Treatment. On the other hand, UAE market is expected to grow at significant rate in the Middle East and Africa HIV Diagnosis & Treatment during the forecasted period. Saudi Arabia is likely to have a limited but moderate growth in the market.
The report for Middle East and Africa HIV Diagnosis & Treatment Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Intended Audience
- Hospitals and Clinics
- HIV Diagnosis & Treatment drugs manufacturers
- HIV Diagnosis & Treatment drugs suppliers
- Government and Independent Regulatory Authorities
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Potential Investors
Report Attribute/Metric
|
Details
|
Market Size
|
USD 12.7 billion
|
CAGR
|
2.9% (2023-2032)
|
Base Year
|
2021
|
Forecast Period
|
2023-2032
|
Historical Data
|
2020
|
Forecast Units
|
Value (USD Billion)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Diagnosis, Treatment
|
Geographies Covered
|
South Africa, Egypt, Nigeria, Morocco and Algeria
|
Key Vendors
|
Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (US), Cipla Inc. (India), F. Hoffmann-La Roche Ltd (Switzerland), Gilead (US), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc.(US), ViiV Healthcare group of companies (UK), Merck & Co., Inc. (US).
|
Key Market Opportunities
|
UAE market is expected to grow at significant rate in the Middle East and Africa HIV Diagnosis & Treatment
|
Key Market Drivers
|
|
HIV Diagnosis Treatment Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report